Immunitas Therapeutics Raises $58M Series B
Gunderson Dettmer represented Immunitas Therapeutics, an immuno-oncology biotech company in its $58 million Series B financing round. The round will advance their efforts to push a new class of checkpoint inhibitors on to the next stop.
In the announcement of the transaction, CEO Jeffrey Goldberg emphasized the two-year-old company's quick clinical ambitions. "Immunitas derives from the research of scientists at Harvard's Dana-Farber Cancer Institute, the Massachusetts Institute of Technology and Massachusetts General Hospital. The single-cell sequencing platform gives Immunitas "a lot of powerful data" about every cell in any human tissue sample that it processes," said Goldberg.
The company first emerged in 2019 with funding from Big Pharmas like Bayer and Novartis, through their venture outfits, along with other investment firms.
The Gunderson deal was led by Timothy Ehrlich, George Pothoulakis, Taylor Sarkaria, Chris Warren, and Joel Diamond.